Phase IIIActive✓ PAG Endorsed by Breast Cancer Research Foundation

Olaparib Maintenance Therapy in BRCA1/2 Mutated HER2-Negative Metastatic Breast Cancer

AstraZeneca·NCT05312904·Breast Cancer

Duration

36 months

Cost

Free to Patients

Phase

Phase III

Closes

Jan 2026

About This Trial

Evaluating olaparib as maintenance therapy for BRCA1/2 mutated HER2-negative metastatic breast cancer.

Trial Locations

New York, NY

Los Angeles, CA

Eligibility & What to Expect

Condition focus: Breast Cancer

Available in: US

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Patient Advocacy Endorsed

Breast Cancer Research Foundation endorses this trial

This trial has been reviewed and endorsed by Breast Cancer Research Foundation. PAG endorsement means patient advocates have evaluated the trial design, risk-benefit profile, and patient-friendliness of this study.

Only 12 spots remaining

Apply soon to secure your place.

Trial Summary

NCT NumberNCT05312904

SponsorAstraZeneca

PhasePhase III

Duration36 months

ClosesJan 2026

ConditionBreast Cancer

Other Breast Cancer Trials

Phase IIIBreast Cancer✓ PAG Endorsed

Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone in HER2-Negative Breast Cancer

Merck Sharp & Dohme

Evaluating whether adding pembrolizumab to chemotherapy improves outcomes in HER2-negative breast cancer.

24 monthsBoston, MA$0